2014
Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH
Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E, Lee O, Kim W, Moon S, Kim I, Choi Y, Kim W. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals Of Surgical Oncology 2014, 22: 2439-2445. PMID: 25348783, DOI: 10.1245/s10434-014-4194-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorCalgranulin ACalgranulin BCase-Control StudiesFollow-Up StudiesHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNucleic AcidsPrognosisProstatic HyperplasiaProstatic NeoplasmsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsS100A8/A9CAP patientsAcid levelsNucleic acid levelBPH tissueProstate cancerS100A8/A9 expressionBenign prostatic hyperplasia tissuesRecurrence-free timeProstatic hyperplasia tissuesUrinary nucleic acidsBPH patientsIndependent predictorsTransurethral resectionAggressive diseaseChronic inflammationPoor prognosisPrognostic valueTransurethral prostatectomyProstatectomy patientsBiochemical recurrencePrognostic markerS100A9 expressionA9 expressionImmunohistochemical staining
2012
Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer
Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.Peer-Reviewed Original ResearchConceptsMetastatic diseaseGleason scoreProstate cancerMRNA expressionElevated PSA levelsNon-metastatic diseaseCase-control studyLow Gleason scoreRunx2 expressionHuman prostate tissuePSA levelsBPH patientsClinicopathological characteristicsClinicopathological outcomesCommon cancerLower PSAPrognostic markerReal-time PCRImmunohistochemical stainingImmunohistochemical analysisTranscription factor 2BPH controlProstate tissueRunx2 mRNA expressionCaP aggressiveness